Scholarlink

Purpose <p>To evaluate the effect of intraoperative administration of 1&#xa0;g of tranexamic acid (TXA) on perioperative and postoperative outcomes in patients receiving antithrombotic therapy undergoing endoscopic enucleation of the prostate (EEP).</p> Methods <p>This multicenter, prospective, observational study included 932 patients across 30 centers (December 2024–June 2025). Patients were divided into four groups based on TXA use and continuation or discontinuation of blood thinners during EEP. The primary endpoint was bleeding complications within 30 days, defined as a composite of transfusion, clot retention, bleeding requiring restart of continuous bladder washout (CBWO), or surgical reintervention to control hemostasis. Multivariable Logistic regression analysis identified independent predictors of bleeding complications.</p> Results <p>There were 534 patients in Group 1 (stopped blood thinners, no TXA given), 316 in Group 2 (on blood thinners, no TXA given), 69 in Group 3 (stopped blood thinners, TXA given), and 13 in Group 4 (on blood thinners, TXA given). Median total operative time was longest in Group 2 (88&#xa0;min [IQR 70–127]) and shortest in Group 3 (55&#xa0;min [IQR 39–69]). Hemostasis time was shortest in TXA groups (<i>p</i> &lt; 0.001). Transfusions occurred in 0.6–7.7% and surgical reinterventions in 0.6–7.7% across groups (<i>p</i> &lt; 0.001). At 3 months, urinary symptoms and continence were comparable. On multivariable analysis, TXA reduced the odds of bleeding complications (OR 0.17, <i>p</i> &lt; 0.001), while ongoing anticoagulant therapy (OR 2.93, <i>p</i> = 0.01), dual therapy (OR 4.31, <i>p</i> &lt; 0.001), and longer operative time (OR 1.01, <i>p</i> &lt; 0.001) increased the odds.</p> Conclusions <p>Intraoperative TXA might mitigate perioperative bleeding and potentially protect patients at higher hemorrhagic risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Influence of intraoperative tranexamic acid on bleeding outcomes in patients receiving antithrombotic therapy undergoing endoscopic enucleation of the prostate: a multicenter prospective study by the endourology section of EAU

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Angelo Cormio,
  • Vineet Gauhar,
  • Thomas Herrmann,
  • Steffi Kar-Kei Yuen,
  • Khi Yung Fong,
  • Steeve Doizi,
  • Stefano Moretto,
  • Marek Zawadzki,
  • Yiloren Tanidir,
  • Mehmet Ilker Gökce,
  • Abhay Mahajan,
  • Dmitriy Sytnik,
  • Abdulrahman Alkandari,
  • Benedikt Becker,
  • Cemil Aydin,
  • Nebil Akdogan,
  • Ender Cem Bulut,
  • Sumit More,
  • Vincent De Coninck,
  • Abai Xu,
  • Nariman Gadzhiev,
  • Vigen Malkhasyan,
  • Karl Tan,
  • Yong Wei Lim,
  • Mahmoud Laymon,
  • Giorgio Mazzon,
  • Sarvajit Biligere,
  • Mallikarjuna Chiruvella,
  • Dmitry Enikeev,
  • Carlo Giulioni,
  • Omar AbdelAziz,
  • Bhaskar Somani,
  • Daniele Castellani

摘要

Purpose

To evaluate the effect of intraoperative administration of 1 g of tranexamic acid (TXA) on perioperative and postoperative outcomes in patients receiving antithrombotic therapy undergoing endoscopic enucleation of the prostate (EEP).

Methods

This multicenter, prospective, observational study included 932 patients across 30 centers (December 2024–June 2025). Patients were divided into four groups based on TXA use and continuation or discontinuation of blood thinners during EEP. The primary endpoint was bleeding complications within 30 days, defined as a composite of transfusion, clot retention, bleeding requiring restart of continuous bladder washout (CBWO), or surgical reintervention to control hemostasis. Multivariable Logistic regression analysis identified independent predictors of bleeding complications.

Results

There were 534 patients in Group 1 (stopped blood thinners, no TXA given), 316 in Group 2 (on blood thinners, no TXA given), 69 in Group 3 (stopped blood thinners, TXA given), and 13 in Group 4 (on blood thinners, TXA given). Median total operative time was longest in Group 2 (88 min [IQR 70–127]) and shortest in Group 3 (55 min [IQR 39–69]). Hemostasis time was shortest in TXA groups (p < 0.001). Transfusions occurred in 0.6–7.7% and surgical reinterventions in 0.6–7.7% across groups (p < 0.001). At 3 months, urinary symptoms and continence were comparable. On multivariable analysis, TXA reduced the odds of bleeding complications (OR 0.17, p < 0.001), while ongoing anticoagulant therapy (OR 2.93, p = 0.01), dual therapy (OR 4.31, p < 0.001), and longer operative time (OR 1.01, p < 0.001) increased the odds.

Conclusions

Intraoperative TXA might mitigate perioperative bleeding and potentially protect patients at higher hemorrhagic risk.